Pharmafile Logo
Pharmafocus logo
Advanced Search

epilepsy

Showing 7 posts of 52 posts found.

Zonegran study could pave way for paediatric licence

September 2, 2011
Research and Development, Sales and Marketing Eisai, Zonegran, epilepsy, research and development news

Eisai’s epilepsy drug Zonegran has been found more effective than placebo in children with the neurological condition who have seizures. …

News
FDA building

FDA refuses to file Eisai’s epilepsy drug

August 1, 2011
Sales and Marketing Eisai, FDA, epilepsy

The FDA has refused to file Eisai’s epilepsy drug perampanel, saying it needs more information for the treatment. The FDA …

News
GlaxoSmithKline

GSK’s epilepsy treatment Potiga wins US approval

June 13, 2011
Sales and Marketing GSK, Potiga, Trobalt, Valeant, epilepsy

The FDA has approved GlaxoSmithKline and Valeant’s epilepsy treatment Potiga, but the drug will require further review before it can …

News

GSK’s Trobalt launched in UK

May 25, 2011
Sales and Marketing GlaxoSmithKline, Trobalt, epilepsy, retigabine

GSK has launched its new epilepsy treatment Trobalt in the UK. Trobalt (retigabine) is as adjunctive treatment of partial onset …

News

GSK and Valeant’s epilepsy treatment approved

April 8, 2011
Sales and Marketing GSK, Trobalt, Valeant, epilepsy

The European Commission has granted marketing authorisation for Trobalt, the new epilepsy drug from GSK and Valeant. Trobalt (retigabine) has …

News

Encouraging data for Eisai epilepsy drug

August 24, 2010
Sales and Marketing Eisai, epilepsy, perampanel, phase III, seizures, study 306

A new phase III study for Eisai’s perampanel (E2007) suggests the first-in-class treatment is effective as an adjunctive treatment of …

News

Slow recovery expected for epilepsy market

May 27, 2010
Sales and Marketing Datamonitor, Keppra, UCB, epilepsy

The global market for epilepsy treatments is expected to make a slow recovery after a wave of patent expiries from …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026